184.85
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$189.26
Offen:
$189.62
24-Stunden-Volumen:
4.95M
Relative Volume:
0.73
Marktkapitalisierung:
$326.52B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
78.66
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
-3.48%
1M Leistung:
-0.24%
6M Leistung:
+7.09%
1J Leistung:
+7.27%
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
![]()
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-11-04 | Hochstufung | Argus | Hold → Buy |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
2023-10-20 | Fortgesetzt | UBS | Neutral |
2023-09-29 | Eingeleitet | Raymond James | Outperform |
2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-05 | Herabstufung | Argus | Buy → Hold |
2023-03-01 | Eingeleitet | Guggenheim | Buy |
2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2022-02-28 | Herabstufung | UBS | Buy → Neutral |
2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
2022-02-03 | Bestätigt | Barclays | Equal Weight |
2022-02-03 | Bestätigt | BofA Securities | Neutral |
2022-02-03 | Bestätigt | Goldman | Neutral |
2022-01-13 | Eingeleitet | Redburn | Buy |
2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
2020-11-10 | Fortgesetzt | Bernstein | Outperform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | Hochstufung | Argus | Hold → Buy |
2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-02-06 | Eingeleitet | Mizuho | Buy |
2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2019-12-26 | Bestätigt | Cowen | Outperform |
2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-05-28 | Eingeleitet | Goldman | Neutral |
2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
What drives AbbVie Inc. stock priceFree Technical Analysis Support - PrintWeekIndia
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
Is AbbVie Inc. a good long term investmentMassive stock growth - PrintWeekIndia
What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year - The Motley Fool
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN
AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks
AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks
AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire
AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks
Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox
Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit
AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks
AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks
AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks
AbbVie’s Venetoclax Study in Greece: A Closer Look at CLL Treatment Outcomes - TipRanks
AbbVie’s Real-World Study on Upadacitinib for Crohn’s Disease: Key Insights for Investors - TipRanks
AbbVie’s Real-World Study on OZURDEX: A Closer Look at Market Implications - TipRanks
AbbVie’s Pediatric IBS-D Study: A Potential Game-Changer for Eluxadoline - TipRanks
AbbVie Completes Phase 1 Trial of ALIA-1758: Key Insights for Investors - TipRanks
AbbVie: Why I Set A $175 Buy Order (NYSE:ABBV) - Seeking Alpha
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times
Glenmark Pharma will turn cash positive with AbbVie's licensing deal S P - theweek.in
Immunology Market Growth in Future Scope 2025-2032 | AbbVie - openPR.com
AbbVie's (NYSE:ABBV) Investors Will Be Pleased With Their Strong 138% Return Over the Last Five Years - 富途牛牛
AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company - Yahoo Finance
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):